Finance

Lists
COHANCE:NSE
Cohance Lifesciences Ltd
₹450.50
-2.70%
(-12.50) 1D
Aug 24, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for COHANCE...
Open
₹458.45
High
₹460.25
Low
₹446.05
Mkt. cap
172.36B
Avg. vol.
0.00
Volume
909.43K
P/E ratio
163.22
52-wk high
₹1,038.90
52-wk low
₹266.70
EPS
₹2.76
No. of employees
1K
Open
₹458.45
High
₹460.25
Low
₹446.05
Mkt. cap
172.36B
Avg. vol.
0.00
Volume
909.43K
P/E ratio
163.22
52-wk high
₹1,038.90
52-wk low
₹266.70
EPS
₹2.76
No. of employees
1K
About Cohance Lifesciences Ltd
CEO-
Employees1.21K
Founded1989
Headquarters-
SectorPharmaceutical industry
Last report
Aug 5, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
-₹0.63 / ₹1.00
-163.00%miss
Revenue / Est. (INR)
4.22B / 5.00B
-15.61%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.56B
5.45B
6.19B
4.22B
Cost of goods sold
1.41B
1.59B
2.14B
1.20B
Cost of revenue
1.41B
1.59B
2.14B
1.20B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.27B
1.19B
1.29B
1.33B
Operating expense
3.38B
3.37B
3.57B
3.50B
Total operating expenses
4.79B
4.96B
5.72B
4.71B
Operating income
769.30M
484.10M
474.50M
-483.80M
Other non operating income
156.00M
61.60M
-18.40M
122.50M
EBT including unusual items
837.70M
406.00M
199.10M
-428.70M
EBT excluding unusual items
837.70M
454.60M
364.20M
-428.70M
Income tax expense
173.80M
115.80M
116.00M
23.20M
Effective tax rate
20.75%
28.52%
58.26%
-5.41%
Other operating expenses
1.67B
1.72B
1.77B
1.68B
Net income
740.80M
367.20M
195.50M
-241.20M
Net profit margin
13.33%
6.74%
3.16%
-5.71%
Earnings per share
1.93
0.55
0.68
-0.63
Interest and investment income
-
-
-
-
Interest expense
-87.60M
-91.10M
-91.90M
-67.40M
Net interest expenses
-87.60M
-91.10M
-91.90M
-67.40M
Depreciation and amortization charges
440.20M
469.40M
512.30M
495.40M
EBITDA
1.23B
677.82M
942.82M
-15.48M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps